What Researchers Did
Researchers reviewed the current literature on various inhaled therapeutics for migraine treatment, including drugs like dihydroergotamine mesylate and prochlorperazine, as well as oxygen and nitrous oxide therapies.
What They Found
In phase 3 studies, inhaled dihydroergotamine mesylate (MAP0004) demonstrated promising efficacy for acute migraine with a favorable tolerability profile. In phase 2 trials, inhaled prochlorperazine showed good pharmacokinetics and efficacy, while inhaled loxapine did not yield encouraging results. The authors suggest that dihydroergotamine mesylate has potential for clinical use pending regulatory approval.
Canadian Relevance
This review article does not have a direct Canadian connection.
Study Limitations
As a review article, this study synthesizes existing literature and does not present new primary research data.